RT Journal Article
SR Electronic
T1 Click-to-Release: Cleavable Radioimmunoimaging with <sup>89</sup>Zr-DFO-<em>Trans</em>-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2023.03.27.534155
DO 10.1101/2023.03.27.534155
A1 Maria Vlastara
A1 Raffaella Rossin
A1 Freek J.M. Hoeben
A1 Kim E. de Roode
A1 Milou Boswinkel
A1 Laurens H.J. Kleijn
A1 James Nagarajah
A1 Mark Rijpkema
A1 Marc S. Robillard
YR 2023
UL http://biorxiv.org/content/early/2023/03/30/2023.03.27.534155.abstract
AB One of the main challenges of PET imaging with 89Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [89Zr]Zr-DFO from trans-cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice.Methods We created a series of TCO-DFO constructs and evaluated their performance in [89Zr]Zr-DFO release from Tmab in vitro using different trigger compounds. The in vivo behavior of the best performing [89Zr]Zr-TCO-Tmab was studied in healthy mice first, to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [89Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [89Zr]Zr-TCO-Tmab-administration in tumor-bearing mice to liberate the [89Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[89Zr]Zr-TCO-Tmab administration.Results The [89Zr]Zr-TCO-Tmab and trigger pair with the best in vivo properties exhibited 83% release in 50 % mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p=0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p&lt;0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [89Zr]Zr-DFO-containing fragment from the circulation through the kidneys.Conclusions This is the first demonstration of the use of trans-cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging.Competing Interest Statementemployee and/or shareholder of Tagworks